David Monteith

David Monteith has over 30 years of work experience in the pharmaceutical industry. David currently holds the position of Executive Director of Clinical Science at Eli Lilly and Company since 2024. Prior to this, they served as the Senior Director of Clinical Science at DICE Therapeutics, Inc., a subsidiary of Eli Lilly and Company, from 2023. From 2021 to 2022, they worked at Clovis Oncology as the Director of Clinical Sciences. David also held the role of Senior Director of Product Development at Omeros Corporation from 2017 to 2021. Before that, they worked as the Senior Director of Clinical Science at Xenon Pharmaceuticals Inc. from 2016 to 2017. David has a long history with Eli Lilly and Company, where they worked as an Asset Manager/Research Advisor from 2005 to 2015 and as a Principal Research Scientist from 2000 to 2005. David also held positions at Charles River/Sierra Biomedical as the Director of Toxicology and Pharmacokinetics from 1999 to 2000, at Ionis Pharmaceuticals as the Assistant Director of Toxicology from 1995 to 1998, and at Parke Davis as a Principal Research Scientist from 1990 to 1995.

David Monteith holds a Bachelor of Science (BS) degree in Environmental Health from the University of Washington, which they obtained from 1977 to 1981. David then pursued higher education at The University of Texas Health Science Center at Houston (UTHealth Houston) from 1981 to 1985, completing a Master of Science (MS) and PhD in Industrial Hygiene and Toxicology. Additionally, they hold the certification of Diplomate American Board of Toxicology from the American Board of Toxicology, Inc.